Cyril Titeux is Company Group Chairman, Johnson & Johnson Innovative Medicine Asia Pacific, and a member of the Innovative Medicine Group Operating Committee (GOC), overseeing the business which focuses on meeting the needs of patients, healthcare providers, and government health bodies across key markets in the region. These include Japan, China, Australia & New Zealand, South Korea, Singapore, and more.
Having spent over 25 years at Johnson and Johnson, Cyril’s experience spans across several continents. Prior to his current role, Cyril served as Vice President and Managing Director of Mid-Sized Markets Europe Region (EMEA), leading teams across 31 markets. During this time, he also served as Vice-Chair of the EFPIA European Markets Committee.
Cyril joined Johnson & Johnson in 1997, gaining sales, marketing and leadership experience across therapeutic areas with Janssen France. He relocated to the US to serve as Global Marketing Leader for Virology. After returning to the EMEA (Europe, Middle East and Africa) region, Cyril served as Managing Director of Janssen Austria, becoming President of Janssen France in 2015. Cyril later became Vice President, EMEA Strategy Organization where he led the regional commercial, medical affairs and market access functions.
After graduating as a Veterinary Doctor from the National Veterinary School of Maisons-Alfort in France, Cyril earned his MBA from the HEC Business School in Paris. He started his pharmaceutical career with Eli Lilly, where he held various positions in sales, market research and marketing.
As a cycling enthusiast, Cyril initiated ‘Cycling for Children,’ gathering more than 5,000 colleagues across J&J to support children in need.